Press Releases

PITTSBURGH, April 11, 2023 /PRNewswire/ -- LyGenesis, Inc., a clinical-stage biotechnology company developing allogenic cell therapies for large unmet needs, and Imagine Pharma, a biotechnology company focused on the development of its novel polypeptide (IMG-1)...

iTolerance and LyGenesis announced a collaboration to evaluate the potential of iTOL-201 combined with LyGenesis' liver cell therapy (LYG-LIV-100), to enable ectopic livers to be grown without the need or immune...

LyGenesis announced that it has achieved positive in vitro results of a novel combination drug-biologic product for patients with inborn errors of metabolism, adding these orphan pediatric indications to its...

AgeX Therapeutics and LyGenesis announced today that they will proceed to negotiate an agreement for a merger of the two companies.

LyGenesis, Inc. announced that the FDA has cleared its Investigational New Drug application and a study will be conducted on the safety and efficacy of its first-in-class novel cell therapy...

LyGenesis, a clinical-stage biotechnology company announced today the publication of a new peer-reviewed paper published in journal Hepatology on its organ regeneration technology.

LyGenesis, a Juvenescence partner, focused on organ regeneration, announced that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, and the Longevity Vision...